Hims & Hers Health Inc Ordinary Shares - Class A HIMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HIMS is a good fit for your portfolio.
News
-
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
-
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
-
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
-
Hims & Hers shares rally as forecast bumped higher and more profitability said to be ahead
-
Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results
-
Hims & Hers to Announce First Quarter 2024 Financial Results on May 6, 2024
-
Hims & Hers Appoints Christopher Payne, Seasoned Tech Industry Executive, as Newest Board Member
-
Hims & Hers to Participate in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024
Trading Information
- Previous Close Price
- $20.37
- Day Range
- $18.89–20.38
- 52-Week Range
- $5.65–21.44
- Bid/Ask
- $19.32 / $19.60
- Market Cap
- $4.17 Bil
- Volume/Avg
- 16.0 Mil / 8.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- 5,858.22
- Price/Sales
- 4.35
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.06%
Company Profile
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,046
- Website
- https://www.forhims.com
Comparables
Valuation
Metric
|
HIMS
|
NUTX
|
GDRX
|
---|---|---|---|
Price/Earnings (Normalized) | 5,858.22 | — | 25.25 |
Price/Book Value | 12.09 | 0.54 | 4.68 |
Price/Sales | 4.35 | 0.12 | 4.17 |
Price/Cash Flow | 52.99 | 5.02 | 19.77 |
Price/Earnings
HIMS
NUTX
GDRX
Financial Strength
Metric
|
HIMS
|
NUTX
|
GDRX
|
---|---|---|---|
Quick Ratio | 2.25 | 1.60 | 6.79 |
Current Ratio | 2.80 | 1.68 | 7.12 |
Interest Coverage | — | −1.32 | −0.55 |
Quick Ratio
HIMS
NUTX
GDRX
Profitability
Metric
|
HIMS
|
NUTX
|
GDRX
|
---|---|---|---|
Return on Assets (Normalized) | 12.99% | 2.84% | 6.98% |
Return on Equity (Normalized) | 16.29% | 14.31% | 13.70% |
Return on Invested Capital (Normalized) | 15.94% | 6.88% | 8.64% |
Return on Assets
HIMS
NUTX
GDRX
Household & Personal Products Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
PG
| Procter & Gamble Co | Qnjllwdb | Vnmsb | $388.3 Bil | |
UL
| Unilever PLC ADR | Bkzdgjvys | Pgfxg | $135.3 Bil | |
CL
| Colgate-Palmolive Co | Fdzlmpwcx | Gjth | $74.6 Bil | |
KMB
| Kimberly-Clark Corp | Lytsptxvj | Jwzbfcx | $44.9 Bil | |
EL
| The Estee Lauder Companies Inc Class A | Qrytdsvkf | Wglz | $44.2 Bil | |
RBGLY
| Reckitt Benckiser Group PLC ADR | Xysflgsq | Zqgh | $39.0 Bil | |
KVUE
| Kenvue Inc | Wqspyjn | Lppk | $37.0 Bil | |
CHD
| Church & Dwight Co Inc | Pktzzhvn | Vpt | $25.5 Bil | |
CLX
| Clorox Co | Xwbfjdgzx | Hgwhf | $16.0 Bil | |
COTY
| Coty Inc Class A | Njf | Ykgzx | $8.9 Bil |